ReLive Biotechnologies Limited
Xing Zhao, M.D. Ph.D. is the Founder, Chairman & Global CEO of ReLive Biotechnologies Limited. Previously, Zhao was the Managing Director at CO.DON GmbH, and Member of the Board of Directors at Mellitus, LLC where they were involved in developing an in vitro diagnostic test for diabetes detection. They also co-founded SQZ Biotechnologies and Orient Landscape, and served as a Chair of Research Steering Committee at Vericel Corporation. With a background in orthopaedic surgery, plastic surgery, and regenerative medicine, Zhao has made significant contributions to the field of healthcare, life sciences, and biotechnology.
This person is not in any teams
ReLive Biotechnologies Limited
ReLive is a pioneering global biotechnology company, founded in 2021 by a team of distinguished visionaries and accomplished experts in the fields of tissue engineering, regenerative medicine, and cell therapy. Backed by venture capital, along with the acquisition of CO.DON, ReLive brings together a diverse team of scientists, surgeons, managers and regulatory experts with extensive and direct experience in biotechnology, to collaborate and develop groundbreaking treatments that improve patient outcomes. Through our ongoing research and development efforts, we strive to make a lasting impact on the field of biotechnology and cell therapy and revolutionize the treatment of or theopoetic and reconstructive conditions.